alexa Statins in Patients with Chronic Kidney Disease: To Give or Not To Give | OMICS International
ISSN : 2153-2435
Pharmaceutica Analytica Acta

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Statins in Patients with Chronic Kidney Disease: To Give or Not To Give

Camelia C Diaconu*

University of Medicine and Pharmacy “Carol Davila”, Clinical Emergency Hospital of Bucharest, Romania

*Corresponding Author:
Camelia C Diaconu
Clinical Emergency Hospital
Clinic of Internal Medicine Calea Floreasca
8, sector 1, 014461, Bucharest, Romania
Tel: 004 0215992300/102
E-mail: [email protected]

Received Date: November 28, 2015; Accepted Date: November 29, 2015; Published Date: November 30, 2015

Citation Date: Diaconu CC (2015) Statins in Patients with Chronic Kidney Disease: To Give or Not To Give. Pharm Anal Acta 6:448. doi: 10.4172/2153-2435.1000e182

Copyright: © 2015 Diaconu CC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta

Patients with chronic kidney disease (CKD) have a high risk of cardiovascular diseases, which represent the main cause of death in these patients. Dyslipidemia is a frequent paraclinical finding in patients with chronic kideny disease and an important contributor to the further deterioration of renal function. Therefore, lipid lowering treatment is very important in patients with chronic kideny disease. Statins are a widely used class of drugs, for primary and secondary prevention of cardiovascular events and death in patients with confirmed cardiovascular disease or very high risk. They are used not only for their lipid regulation action but also for their pleiotropic effects, such as atheromatous plaques stabilization or antiinflammatory effect. The beneficial effects of statins in preventing the development and progression of renal dysfunction seem to be independent of their lipid-lowering effect. However, in patients with chronic kidney disease, there is a debate on the indications and contraindications of statin treatment, and also on their beneficial effects. In a meta-analysis published in 2013, the authors have found that statin treatment produced a 23% decrease of the risk of major cardiovascular events (but not cerebrovascular disease) or an 18% per 1 mmol/L lowering of LDLcholesterol in patients with CKD (including patients on hemodialysis) [1]. The same authors observed that the beneficial effects of statins were lower in patients with lower estimated GFR (eGFR), in those with stage 5 kidney disease and those requiring hemodialysis. The subgroup analysis indicated that statin effect was significantly influenced by the status of the kidney function. A controversial issue of this meta-analysis was that trials with dialysis and non-dialysis patients were combined, and the statin effects might be different in patients with different grades of CKD.

Another meta-analysis showed similar results by analyzing separately patients with different stages of CKD and renal replacement therapy. They concluded that statins decreased the rate of cardiovascular events and mortality in individuals with early stages of CKD and had no effects in patients with more advanced CKD, on hemodialysis [2].

A number of studies have evaluated the effect of statin treatment on renal outcomes of patients with CKD. There is a known corelation between proteinuria and progression of CKD, on one hand, and between proteinuria and cardiovascular diseases, on the other hand. Therefore, some studies evaluated the effect of statin treatment on proteinuria. A meta-analysis of this studies reported a reduction by 48% of albuminuria in patients with moderately or severely increased albuminuria on statin therapy [3]. Two randomized large studies did not found any effect of statins on albuminuria in hypertensive patients with good blood pressure control under treatment with angiotensin blockers: PREVEND-IT trial and ESPLANADE trial [4,5].

The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline recommends statin treatment for patients with a high cardiovascular risk (history of heart disease, stroke, atherosclerotic peripheral arterial disease, diabetes mellitus, hyperlipidemia or those with an estimated 10-year risk of at least 7.5%); patients already on hemodialysis are unlikely to benefit from statin treatment, therefore no recommendation was made about starting or continuation of statins treatment in these patients [6]. However, the Kidney Disease: Improving Global Outcomes (KDIGO) guideline from 2013 recommends statins in all patients between 50-79 years old with CKD; the same guideline recommend that adults with CKD on dialysis should not begin treatment with statins or statin/ezetimibe and those already taking a statin at the time of dialysis should continue the treatment [7].

In the real life, the statin use among patients with CKD at risk for cardiovascular events is probably lower than among similar patients with normal kidney function.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8028
  • [From(publication date):
    November-2015 - Jul 17, 2018]
  • Breakdown by view type
  • HTML page views : 7966
  • PDF downloads : 62

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version